Brief: Sino Biopharmaceutical's Culmerciclib Capsule Receives NMPA Approval For First-Line Hr+/Her2- Advanced Breast Cancer In China
06/05/2026 12:04
May 6 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: CULMERCICLIB CAPSULE RECEIVES NMPA APPROVAL FOR FIRST-LINE HR+/HER2- ADVANCED BREAST CANCER IN CHINA CULMERCICLIB RECEIVES SECOND INDICATION APPROVAL IN CHINA CULMERCICLIB PLUS FULVESTRANT SHOWS 44% RISK REDUCTION IN PHASE III TRIAL Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up